Frates James M.'s Insider Trades & SAST Disclosures
Frates James M.'s most recent trade in Amylyx Pharmaceuticals Inc was a trade of 10,896 Common Stock done at an average price of $3.5 . Disclosure was reported to the exchange on March 31, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Frates James M..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 31 Mar 2025 | 10,896 | 290,988 | - | 3.5 | 37,806 | Common Stock |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 102,630 | 102,630 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 68,420 | 301,884 | - | 0 | Common Stock | |
| Sage Therapeutics Inc | James M. Frates | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 19,154 | 19,154 | - | - | Stock Options (Right to buy) | |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.53 per share. | 12 Sep 2024 | 40,000 | 233,464 | - | 2.5 | 101,368 | Common Stock |
| Sage Therapeutics Inc | James M. Frates | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 120,000 | 120,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2024 | 91,180 | 225,964 | - | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.73 per share. | 05 Mar 2024 | 1,792 | 134,784 | - | 18.7 | 33,560 | Common Stock |
| Amylyx Pharmaceuticals Inc | M. James Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | Frates James M. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 40,000 | 152,035 | - | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | M. James Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.33 per share. | 09 Jan 2024 | 2,716 | 112,035 | - | 16.3 | 44,347 | Common Stock |
| Sage Therapeutics Inc | M. Frates James | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 4,925 | 4,925 | - | - | Stock Options (Right to buy) | |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Oct 2023 | 11,072 | 11,072 | - | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 23 Aug 2023 | 18,165 | 106,341 | - | 6.9 | 124,975 | Common Stock |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2023 | 18,165 | 363,835 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 23 Aug 2023 | 18,165 | 73,841 | - | 6.9 | 124,975 | Common Stock |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2023 | 18,165 | 363,835 | - | - | Stock Option (right to buy) | |
| Sage Therapeutics Inc | James M. Frates | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2023 | 32,500 | 382,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 16 May 2023 | 32,500 | 88,176 | - | 6.9 | 223,600 | Common Stock |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.93 per share. | 16 May 2023 | 32,000 | 56,176 | - | 26.9 | 861,651 | Common Stock |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.60 per share. | 16 May 2023 | 500 | 55,676 | - | 27.6 | 13,800 | Common Stock |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 97,500 | 97,500 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 16 Mar 2023 | 32,500 | 66,509 | - | 6.9 | 223,600 | Common Stock |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2023 | 32,500 | 414,500 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.86 per share. | 16 Mar 2023 | 30,796 | 35,713 | - | 31.9 | 981,139 | Common Stock |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 21,667 | 55,676 | - | 0 | Common Stock | |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.46 per share. | 16 Mar 2023 | 1,704 | 34,009 | - | 32.5 | 55,320 | Common Stock |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.08 per share. | 06 Jan 2023 | 1,836 | 34,831 | - | 36.1 | 66,241 | Common Stock |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.79 per share. | 06 Jan 2023 | 822 | 34,009 | - | 36.8 | 30,240 | Common Stock |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.88 per share. | 30 Dec 2022 | 5,000 | 36,667 | - | 6.9 | 34,400 | Common Stock |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2022 | 5,000 | 447,000 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | James M. Frates | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,947 | 9,947 | - | - | Stock Option (Right to Buy) | |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | 06 Jan 2022 | 19,482 | 0 | - | - | Series C-1 Preferred Stock | ||
| Amylyx Pharmaceuticals Inc | James M. Frates | Chief Financial Officer | 06 Jan 2022 | 19,482 | 19,482 | - | 0 | Common Stock | ||
| Sage Therapeutics Inc | James M. Frates | Director | Purchase of securities on an exchange or from another person at price $ 55.10 per share. | 16 Jun 2021 | 1,810 | 1,810 (0%) | 0% | 55.1 | 99,735 | Common Stock |
| Sage Therapeutics Inc | James M. Frates | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | James M. Frates | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Alkermes plc | James M. Frates | SVP, Alks Inc; CFO ALKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.74 per share. | 14 May 2020 | 21,983 | 91,828 (0%) | 0% | 11.7 | 258,080 | Ordinary Shares |
| Alkermes plc | James M. Frates | SVP, Alks Inc; CFO ALKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2020 | 21,983 | 0 | - | - | Employee Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges